<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Penicillamine (D-penicillamine): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Penicillamine (D-penicillamine): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Penicillamine (D-penicillamine): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9747" href="/d/html/9747.html" rel="external">see "Penicillamine (D-penicillamine): Drug information"</a> and <a class="drug drug_patient" data-topicid="11406" href="/d/html/11406.html" rel="external">see "Penicillamine (D-penicillamine): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709199"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Experienced physician: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Physicians planning to use penicillamine should thoroughly familiarize themselves with its toxicity, special dosage considerations, and therapeutic benefits. Penicillamine should never be used casually. Each patient should remain constantly under the close supervision of the physician. </p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Toxicity symptoms:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Patients should be warned to report promptly any symptoms suggesting toxicity.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F207480"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cuprimine;</li>
<li>Depen Titratabs</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F57397462"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Cuprimine</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1060964"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidote, Copper Toxicity</span>;</li>
<li>
<span class="list-set-name">Antidote, Lead Toxicity</span>;</li>
<li>
<span class="list-set-name">Chelating Agent, Oral</span></li></ul></div>
<div class="block dop drugH1Div" id="F207504"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Penicillamine administration increases requirement for pyridoxine. Patients may require a daily supplement of pyridoxine. A dose reduction (to 250 mg/day in adults) may be considered prior to surgical procedures. May resume normal recommended dosing postoperatively once wound healing is complete.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="356294e9-9c29-43ce-b91c-44f10819a66f">Wilson disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Wilson disease</b>:</p>
<p style="text-indent:-2em;margin-left:4em;">Diagnosis, adjunct; symptomatic patients: Penicillamine Challenge Test: Limited data available; not sufficiently sensitive in asymptomatic patients (AASLD [Schilsky 2022]): Children ≥2 years and Adolescents: Oral: 500 mg/dose for 2 doses; administer first immediately prior to a 24-hour urine collection and repeat 12 hours later. Urinary copper excretion &gt;1,600 mcg copper/24 hour (&gt;25 µmol/24 hours) is consistent with diagnosis of Wilson disease (AASLD [Schilsky 2022]; EASL 2012; Martins da Costa 1992; Müller 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial:</i> Children and Adolescents: Oral: 20 mg/kg/day in 2 to 3 divided doses, round off to the nearest 250 mg dose; maximum daily adult dose: 2,000 mg/<b>day</b> in divided doses 2 to 4 times daily (AASLD [Schilsky 2022]; EASL 2012).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance (once clinically stable):</i> Children and Adolescents: Oral: 10 to 15 mg/kg/day in divided doses; usual adult doses 750 to 1,000 mg twice daily (AASLD [Schilsky 2022]; EASL 2012).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e3686f85-bf0e-4446-a0dd-4fb669fb496a">Cystinuria</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystinuria: </b>Children and Adolescents: Oral: 20 to 40 mg/kg/day in 4 divided doses; maximum daily dose: 1,200 mg/<b>day</b>; per the manufacturer, adjust dose to limit cysteine excretion to &lt;100 to 200 mg/day (&lt;100 mg/day with history of stone formation and/or pain). <b>Note: </b> If equal doses are not possible, administer the larger portion at bedtime (DeBerardinis 2008; Knoll 2005; Servais 2021; manufacturer's labeling).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ad6c1520-f76f-4866-9ee2-58ecc5033ef3">Lead poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lead poisoning:</b> Limited data available: <b>Note:</b> For the treatment of high blood lead levels in children, the CDC recommends chelation treatment when blood lead levels (BLL) are &gt;45 mcg/dL (ACCLPP 2012; CDC 2002). AAP considers penicillamine a third-line agent for children when BLL &gt;45 mcg/dL and &lt;70 mcg/dL; children with BLL ≥70 mcg/dL or symptomatic lead poisoning should be treated with parenteral agents (AAP [Shenoi 2020]; Calello 2018). Selection of chelating regimen should be made in consultation with a clinical toxicologist or expert in the treatment of heavy metal poisoning.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral: Initial: 10 mg/kg/day divided twice daily for 2 weeks increase dose to 25 to 40 mg/kg/day (Kliegman 2016); increasing the dose over a few weeks has been suggested to improve tolerability (Shannon 1988). A reduced dosage of 15 mg/kg/day in 2 divided doses has been shown to be effective in the treatment of mild to moderate lead poisoning (blood lead concentration 20 to 40 mcg/dL) with a reduction in adverse effects (Shannon 2000); lower doses (10 to 15 mg/kg/day for 4 to 12 weeks) has also been suggested for treating lead concentrations of 45 to 69 mcg/dL (Chandran 2010).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51152528"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; however, the manufacturer’s labeling suggests caution as the drug undergoes mainly renal elimination; drug is dialyzable. Based on experience in adult patients, dosing adjustment suggested (particularly with hemodialysis).</p></div>
<div class="block dohp drugH1Div" id="F51152529"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, only a small fraction is metabolized hepatically.</p></div>
<div class="block doa drugH1Div" id="F207484"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9747" href="/d/html/9747.html" rel="external">see "Penicillamine (D-penicillamine): Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose reduction to 250 <b>mg</b>/day may be considered prior to surgical procedures (including prior to cesarean delivery in pregnant patients with Wilson disease). May resume normal recommended dosing postoperatively once wound healing is complete. Penicillamine administration increases requirement for pyridoxine. Patients may require a daily supplement of pyridoxine (25 to 50 mg/day) (AASLD [Schilsky 2022]; EASL 2012).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e3686f85-bf0e-4446-a0dd-4fb669fb496a">Cystinuria</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystinuria:</b>
<b>Oral:</b> 1 to 4 g/day in 4 divided doses; usual dose: 2 g/day; initiation of therapy at 250 <b>mg</b>/day with gradual upward titration may reduce the risk of unwanted effects. <b>Note:</b> Adjust dose to limit cystine excretion to 100 to 200 mg/day (&lt;100 mg/day with history of stone formation).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="356294e9-9c29-43ce-b91c-44f10819a66f">Wilson disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Wilson disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial phase:</i>
<b>Oral:</b> 250 to 500 <b>mg</b>/day; increase dose in 250 <b>mg</b> increments every 4 to 7 days to 15 to 20 mg/kg/day (~1 to 1.5 <b>g</b>/day) in 2 to 4 divided doses; maximum dose: 2 <b>g</b>/day (AASLD [Schilsky 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance phase:</i>
<b>Oral:</b> Usual maintenance dose of 10 to 15 mg/kg/day (~750 to 1,000 <b>mg</b>/day) in 2 or 3 divided doses (AASLD [Schilsky 2022]; EASL 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pregnancy:</i> Decrease the dose to the minimum effective dose; consider reducing by 25% to 50% of the prepregnancy dose (AASLD [Schilsky 2022]; Dathe 2016; EASL 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Manufacturer's labeling:</i> Dosing in the prescribing information may not reflect current clinical practice.<b> Oral:</b> 750 <b>mg</b> to 1.5 g/day in divided doses; maximum dose: 2 g/day. <b>Note:</b> During pregnancy, limit daily dose to 750 <b>mg</b>/day; if planned cesarean delivery, limit dose to 250 <b>mg</b>/day during the last 6 weeks of pregnancy and postoperatively until wound healing is complete.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992123"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Manufacturer's labeling:</i> There are no dosage adjustments provided in the manufacturer's labeling; however, the manufacturer labeling does suggest a cautious approach to dosing as this drug undergoes mainly renal elimination.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Alternate recommendations:</i></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;50 mL/minute: Avoid use (Aronoff 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Dialyzable: Administer 33% of usual dose (Aronoff 2007).</p></div>
<div class="block doha drugH1Div" id="F50989349"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, only a small fraction is metabolized hepatically.</p></div>
<div class="block adr drugH1Div" id="F207445"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">&gt;10%: Gastrointestinal: Dysgeusia (12%), gastrointestinal signs and symptoms (17%, including anorexia, diarrhea, epigastric pain, nausea, and vomiting)</p>
<p style="text-indent:0em;">1% to 10%:</p>
<p style="text-indent:0em;margin-left:2em;">Dermatologic: Skin rash (5%)</p>
<p style="text-indent:0em;margin-left:2em;">Genitourinary: Proteinuria (6%)</p>
<p style="text-indent:0em;margin-left:2em;">Hematologic &amp; oncologic: Leukopenia (2%), thrombocytopenia (4%)</p>
<p style="text-indent:0em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Exfoliative dermatitis, pruritus, urticaria, yellow nail syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Pancreatitis, peptic ulcer (reactivation)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphadenopathy, positive ANA titer</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic impairment (including hepatic failure)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, dystonia, lupus-like syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Thrombophlebitis, vasculitis (renal vasculitis)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, cheilosis, dermatologic disorder (elastosis perforans serpiginosum) (Atzori 2011), fragile skin (friability increased), lichen planus, papule of skin (white papules at venipuncture and surgical sites), pemphigus (including pemphigus erythematosus, pemphigus foliaceus, and pemphigus vulgaris) (Marsden 1976, Scherak 1977, Szegedi 2004), skin atrophy (anetoderma), toxic epidermal necrolysis, wrinkling of skin (excessive)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoglycemia, increased lactate dehydrogenase, thyroiditis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Glossitis, oral mucosa ulcer, stomatitis (gingivostomatitis)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breast disease (mammary hyperplasia)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, eosinophilia, hemolytic anemia, leukocytosis, monocytosis, pure red cell aplasia, sideroblastic anemia, thrombocytosis, thrombotic thrombocytopenic purpura</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (Rosenbaum 1980), increased serum alkaline phosphatase, intrahepatic cholestasis, toxic hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Anti-GBM disease, dermatomyositis (Wojnarowska 1980)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, anxiety, Guillain-Barré syndrome, myasthenia (including extraocular muscles) (Bucknall 1977, Katz 1989), myasthenia gravis (Sundstrom 1979), neurological deterioration, peripheral motor neuropathy, peripheral sensory neuropathy, psychiatric disturbance (including mental disorders)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myotonia (neuromyotonia) (Reeback 1979), polymyositis (Takahashi 1986)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Optic neuritis, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Kidney failure</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma, bronchiolitis obliterans (Boehler 1996), hypersensitivity pneumonitis, interstitial pneumonitis, pulmonary alveolitis (Davies 1980), pulmonary fibrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Hyperpyrexia, laboratory test abnormality (positive cephalin flocculation and thymol turbidity)</p></div>
<div class="block coi drugH1Div" id="F207461"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Renal insufficiency (in patients with rheumatoid arthritis); patients with previous penicillamine-related aplastic anemia or agranulocytosis; breast-feeding; pregnancy (in patients with rheumatoid arthritis)</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: Additional contraindications (not in US labeling):</i> Hypersensitivity to penicillamine or any component of the formulation; use in patients with chronic lead poisoning who have radiographic evidence of lead-containing substances in the GI tract; pregnancy (in patients with chronic lead poisoning); concomitant use with gold therapy, antimalarial or cytotoxic drugs, oxyphenbutazone or phenylbutazone.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F207442"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Allergic reactions: Approximately 33% of patients will experience an allergic reaction. Rash may occur early (more commonly) or late in therapy. Early-onset rash typically resolves within days of discontinuation of therapy and does not recur upon rechallenge with reduced dose; late-onset rashes (eg, after &gt;6 months) typically recur with rechallenge.</p>
<p style="text-indent:-2em;margin-left:4em;">• Anti-glomerular basement membrane (GBM) disease (Goodpasture syndrome): Penicillamine has been associated with fatalities due to anti-GBM disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bronchiolitis obliterans: Has been reported rarely with use; instruct patients to report pulmonary symptoms (eg, unexplained wheezing or cough, exertional dyspnea) and consider pulmonary function testing in such patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic: Penicillamine increases the amount of soluble collagen; may increase skin friability, particularly at sites subject to pressure or trauma (eg, knees, elbows, shoulders). Purpuric areas with localized bleeding (if skin is broken) or vesicles with dark blood may be observed. Effects are considered localized and do not necessitate discontinuation of therapy; may not recur with dose reduction. Macular cutaneous eruptions are sometimes observed in conjunction with drug fever, usually 2 to 3 weeks after therapy initiation. Dose reduction may be considered prior to surgical procedures. May resume normal recommended dosing postoperatively once wound healing is complete.</p>
<p style="text-indent:-2em;margin-left:4em;">• Drug fever: Drug fever may be observed, usually 2 to 3 weeks after therapy initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal: Taste alteration may occur (rare in Wilson disease); usually self-limited with continued therapy; however, may last ≥2 months and result in total loss of taste. Oral ulceration (eg, stomatitis) may occur; typically recurs on rechallenge but often resolves with dose reduction. Other dose-related lesions (eg, glossitis, gingivostomatitis) have been observed with use and may require therapy discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic toxicities: Penicillamine has been associated with fatalities due to agranulocytosis, aplastic anemia, and thrombocytopenia. Monitor for signs/symptoms of leukopenia and thrombocytopenia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Monitor LFTs periodically due to rare reports of intrahepatic cholestasis or toxic hepatitis. More frequent monitoring is required during the first year of therapy in patients with Wilson disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lupus erythematosus-like syndrome: May be observed in some patients; positive antinuclear antibody (ANA) test does not necessitate therapy discontinuation but should alert clinicians of possible future development of lupus erythematosus-like syndrome.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pemphigus: May occur early or late in therapy; discontinue use with suspicion of pemphigus. May treat with high-dose corticosteroids alone, or in conjunction with an immunosuppressant; treatment duration can range from weeks to &gt;1 year.</p>
<p style="text-indent:-2em;margin-left:4em;">• Penicillin cross-sensitivity: Patients with a penicillin allergy may theoretically have cross-sensitivity to penicillamine; however, the possibility has been eliminated now that penicillamine is produced synthetically and no longer contains trace amounts of penicillin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Proteinuria/hematuria: Proteinuria or hematuria may develop; monitor for membranous glomerulopathy which can lead to nephrotic syndrome. Dose reduction may lead to resolution of proteinuria.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Penicillamine has been associated with myasthenic syndrome, and in some cases, progression to myasthenia gravis. Resolution of symptoms has been observed in most cases following discontinuation of therapy. Avoid use in patients with myasthenia gravis (AAN [Narayanaswami 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Toxicity symptoms: <b>[US Boxed Warning]: Patients should be warned to report promptly any symptoms suggesting toxicity (fever, sore throat, chills, bruising, or bleeding);</b> toxicity may be dose related.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cystinuria: Continue treatment on a daily basis; interruptions of even a few days have been followed by hypersensitivity with reinstitution of therapy. Patients should receive pyridoxine supplementation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lead poisoning: Investigate, identify, and remove sources of lead exposure prior to treatment; do not permit patients to re-enter the contaminated environment until lead abatement has been completed. Consultation with a clinical toxicologist or an expert in the treatment of heavy metal poisoning is highly recommended before initiating chelation therapy. Penicillamine is considered to be a third-line agent for the treatment of lead poisoning in children due to the overall toxicity associated with its use (AAP 2005; Calello 2018; Chandran 2010); penicillamine should only be used when unacceptable reactions have occurred with edetate CALCIUM disodium and succimer in patients who require chelation (Calello 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Wilson disease: Continue treatment on a daily basis; interruptions of even a few days have been followed by hypersensitivity with reinstitution of therapy. Worsening of neurologic symptoms may occur during initiation of therapy, however, discontinuation of therapy is not recommended; tolerability may be enhanced by starting with incremental doses (EASL 2012). May consider concomitant use of short-term dimercaprol in patients whose symptoms continue to worsen 1 month following therapy initiation. Patients should receive pyridoxine supplementation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hematopoietic-depressant drugs: Use with caution in patients on other hematopoietic-depressant drugs (eg, gold, immunosuppressants, antimalarials, phenylbutazone; Canadian labeling contraindicates concomitant use with these agents); hematologic and renal adverse reactions are similar.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly; may be more susceptible to skin rash and/or taste alterations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Experienced physician: <b>[US Boxed Warning]: Should be administered under the close supervision of a physician familiar with the toxicity and dosage considerations. </b></p></div>
<div class="block foc drugH1Div" id="F207453"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cuprimine: 250 mg [contains quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Depen Titratabs: 250 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg</p></div>
<div class="block geq drugH1Div" id="F207438"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F207463"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Cuprimine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $314.26</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (penicillAMINE Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $251.41 - $298.55</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Depen Titratabs Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $86.43</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (penicillAMINE Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $65.43</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F57397463"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cuprimine: 250 mg [contains quinoline yellow (d&amp;c yellow #10)]</p></div>
<div class="block exp drugH1Div" id="F207459"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">A 50 mg/mL oral suspension may be made with capsules. Mix the contents of sixty 250 mg capsules with 3 g carboxymethylcellulose, 150 g sucrose, 300 mg citric acid, and parabens (methylparaben 120 mg, propylparaben 12 mg). Add quantity of propylene glycol sufficient to make 100 mL, then add quantity of purified water sufficient to make 300 mL. Cherry flavor may be added. Label "shake well" and "refrigerate". Stable for 30 days refrigerated.</p>
<div class="reference">DeCastro FJ, Jaeger RQ, and Rolfe UT, "An Extemporaneously Prepared Penicillamine Suspension Used to Treat Lead Intoxication," <i>Hosp Pharm</i>, 1977, 2:446-8.</div>
</div>
<div class="block admp drugH1Div" id="F52613556"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer on an empty stomach (1 hour before or 2 hours after meals) and at least 1 hour apart from other drugs, milk, antacids, and zinc or iron-containing products. Patients unable to swallow capsules may mix contents of capsule with fruit juice or chilled pureed fruit (Cuprimine prescribing information [Canada] 2012). Doses ≤500 mg may be administered as single dose; doses &gt;500 mg should be administered in divided doses.</p>
<p style="text-indent:0em;margin-top:2em;">Cystinuria: If administering 4 equal doses is not feasible, administer the larger dose at bedtime. Patients with cystinuria should drink copious amounts of water.</p></div>
<div class="block adm drugH1Div" id="F207457"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Doses ≤500 mg may be administered as a single dose; doses &gt;500 mg should be administered in divided doses. For patients who have difficulty swallowing, the contents of the capsules may be administered in 15 to 30 mL of chilled puréed fruit or fruit juice within 5 minutes of preparation. Administer on an empty stomach (1 hour before or 2 hours after meals) and at least 1 hour apart from other drugs, milk, antacids, iron-containing products, and zinc-containing products. Administration closer to meals may be considered if it improves adherence but closer monitoring is required (AASLD [Schilsky 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">Cystinuria: If administering 4 equal doses is not feasible, administer the larger dose at bedtime. Patients should drink about one pint of fluid at bedtime and another pint during the night.</p></div>
<div class="block sts drugH1Div" id="F207474"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store in tight, well-closed containers.</p></div>
<div class="block usep drugH1Div" id="F53568288"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of Wilson disease (FDA approved in pediatric patients [age not specified] and adults), treatment of cystinuria (FDA approved in pediatric patients [age not specified] and adults), adjunct treatment of severe active rheumatoid arthritis when conventional therapy has failed (FDA approved in adults); has also been used for diagnosis of Wilson disease and treatment of lead poisoning. <b>Note:</b> Although penicillamine has historically been used in the management of rheumatoid arthritis in adults, it is not mentioned in current clinical practice guidelines from the American College of Rheumatology for the treatment of rheumatoid arthritis (ACR [Fraenkel 2021]). Penicillamine use is associated with significant toxicity, including membranous glomerulonephritis, a type of nephrotic syndrome (Nagahama 2002). Use should be avoided due to the availability of alternative agents with less risk of toxicity.</p></div>
<div class="block mst drugH1Div" id="F207532"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Penicillamine may be confused with penicillin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (when used for rheumatoid arthritis) among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Depen [U.S.] may be confused with Depin brand name for nifedipine [India]; Depon brand name for acetaminophen [Greece]; Dipen brand name for diltiazem [Greece]</p>
<p style="text-indent:-2em;margin-left:4em;">Pemine [Italy] may be confused with Pamine brand name for methscopolamine [U.S., Canada]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299837"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F207447"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: PenicillAMINE may decrease the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: PenicillAMINE may enhance the therapeutic effect of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: May decrease the absorption of PenicillAMINE. Management: Give penicillamine at least 2 hours before or at least 6 hours after polyethylene glycol-electrolyte solutions that contain magnesium sulfate (Suflave brand). Other products without magnesium do not require dose separation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyvalent Cation Containing Products: May decrease the serum concentration of PenicillAMINE. Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F207475"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Penicillamine serum levels may be decreased if taken with food. Management: Administer on an empty stomach 1 hour before or 2 hours after meals and at least 1 hour apart from other drugs, milk, antacids, iron-containing products, and zinc-containing products. Certain disease states require further diet adjustment.</p></div>
<div class="block dic drugH1Div" id="F207465"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Should be taken at least 1 hour before or 2 hours after meals on an empty stomach (<b>Note:</b> Canadian labeling recommends administration at least 2 hours before meals in patients with lead poisoning). Pyridoxine supplementation is recommended. Patients with Wilson disease should receive 25 to 50 mg/day of pyridoxine (Roberts 2008); a multivitamin (without copper) may also be considered. Patients with cystinuria or patients with rheumatoid arthritis and impaired nutritional intake should receive 25 mg/day of pyridoxine. For Wilson disease, decrease copper in diet to &lt;1 to 2 mg/day and omit chocolate, nuts, shellfish, mushrooms, liver, raisins, broccoli, copper-enriched cereal, multivitamins with copper, and molasses. May consider short courses of iron supplementation if dietary modifications (eg, low copper diet in Wilson disease, low methionine diet in cystinuria) results in iron deficiency; pediatric patients and menstruating women may be particularly susceptible to iron deficiency. Allow at least 1 hour between administration of iron supplementation and penicillamine as iron may decrease drug absorption. For cystinuria, increase daily fluid intake, including 1 pint (~500 mL) of fluid prior to bedtime and 1 additional pint during the night. For lead poisoning, decrease calcium in diet.</p></div>
<div class="block pri drugH1Div" id="F207464"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Penicillamine-disulphide and cysteine-penicillamine were present in the urine of a newborn following maternal use of penicillamine throughout pregnancy for the treatment of cystinuria (Crawhall 1967).</p>
<p style="text-indent:0em;margin-top:2em;">Birth defects, including congenital cutix laxa and associated defects, have been reported in infants following penicillamine exposure during pregnancy; however, outcome information related to use in pregnancy is limited (AASLD [Schilsky 2022]; Dathe 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Continued treatment of Wilson disease during pregnancy protects the mother against relapse. Discontinuation has detrimental maternal and fetal effects. Penicillamine should be decreased to the minimum effective dose during pregnancy to limit fetal exposure during the first trimester, to prevent fetal copper deficiency, and to help promote maternal wound healing if cesarean delivery is planned. Doses may be 25% to 50% of the prepregnancy dose. Close monitoring is recommended (AASLD [Schilsky 2022]; EASL 2012).</p>
<p style="text-indent:0em;margin-top:2em;">Use for the treatment of rheumatoid arthritis during pregnancy is contraindicated. Penicillamine should be used for the treatment of cystinuria only if the possible benefits to the mother outweigh the potential risks to the fetus.</p></div>
<div class="block mopp drugH1Div" id="F53568278"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Urinalysis, CBC with differential, platelet count, skin, lymph nodes, and body temperature twice weekly during the first month of therapy, then every 2 weeks for 5 months, then monthly. Monitor urinalysis for proteinuria and hematuria; if proteinuria develops a quantitative 24-hour urine protein at 1- to 2-week intervals initially (first 2 to 3 months) is recommended. LFTs every 6 months; signs/symptoms of hypersensitivity.</p>
<p style="text-indent:-2em;margin-left:2em;">Cystinuria: 24-hour urinary cysteine (baseline and then every 6 to 12 months), annual X-ray for renal stones; some have recommended renal ultrasound every 6 months to monitor for efficacy and copper and zinc concentrations to monitor toxicity (DeBerardinis 2008).</p>
<p style="text-indent:-2em;margin-left:2em;">Lead poisoning: Serum lead concentration (baseline and 7 to 21 days after completing chelation therapy) (CDC 2002); hemoglobin or hematocrit, iron status, free erythrocyte protoporphyrin or zinc protoporphyrin; neurodevelopmental changes.</p>
<p style="text-indent:-2em;margin-left:2em;">Wilson disease: Periodic 24-hour urinary copper assessment (at minimum twice yearly; more frequently until stable, if dose is adjusted, if side effects present, or if there is a question of adherence); serum non-ceruloplasmin bound copper; physical exam (liver disease/neurological symptoms), LFTs, CBC, INR, ferritin levels, and urinalysis (weekly during initiation, then every 1 to 3 months until remission, followed by every 3 to 6 months); periodic ophthalmic exam (AASLD [Schilsky 2022]; EASL 2012).</p></div>
<div class="block rerp drugH1Div" id="F53568084"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Wilson disease: Adequate treatment, chronic therapy: Serum non-ceruloplasmin bound copper 5 to 15 mcg/dL (Serum non-ceruloplasmin bound copper = Total copper − ceruloplasmin copper); 24-hour urinary copper excretion 200 to 500 mcg (3 to 8 micromoles)/day (AASLD [Schilsky 2022]; ESPGHAN [Socha 2018]).</p></div>
<div class="block pha drugH1Div" id="F207441"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Chelates with lead, copper, mercury and other heavy metals to form stable, soluble complexes that are excreted in urine; depresses circulating IgM rheumatoid factor, depresses T-cell but not B-cell activity; combines with cystine to form a compound which is more soluble, thus cystine calculi are prevented</p></div>
<div class="block phk drugH1Div" id="F207460"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Rheumatoid arthritis: 2 to 3 months; Wilson disease: 1 to 3 months</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid but incomplete (40% to 70%); reduced by food, antacids, and iron</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;80% to albumin and ceruloplasmin</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (small amounts metabolized to s-methyl-d-penicillamine)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 1.7 to 7 hours (Roberts 2008); large variations exist and a slow elimination phase lasting 4 to 6 days may occur after prolonged treatment has been stopped.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 1 to 3 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (primarily as disulfides)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F207466"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cuprimine | Cupripen</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Artamin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">D-penamine</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Byanodine</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Kelatin</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cuprenil</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cuprimine</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Mercaptyl</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Atamir</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cuprimine | Cupripen</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Metalcaptase | Trolovol</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Metalcaptase | Trisorcin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Artamin | Cuprenil | Cupripen | Distamine | Penicillamin | Rhumantin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Artamin | Artamine | Retadel</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cupripen</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Metalcaptase | Penicillamine | Reumacillin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Trolovol</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cuprimine | Depamine | Distamine | Penicillamine cox</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cupripen</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Cuprimine</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Byanodine | Cuprenil | Cupripen</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">D-penamine | Distamine</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Atrmin | Cilamin | Distamin | Penicitin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Pemine</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Artamin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">D penicillamine | Metalcaptase</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Artamin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Artamin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Byanodine | Cuprenil | Metalcaptase | Penicilamin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Kelatin | Metalcaptase</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Artamin | Cuprenil | Metalcaptase | Penicilamin | Rhumantin | Trisorcin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Adalken | Sufortan</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Artamin | Cilamin | Cuprimine | Cupripen | D-penamine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Distamine | Gerodyl | Kelatin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Atamir | Cuprimine | Distamine | Metalcaptase</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">D-penamine | Distamine</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Cuprimine | D-penil | Penicilamina</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Carlton | Cillamin | Vistamin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cuprenil | Metalcaptase</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cuprimine | D-penamine</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Kelatine</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Artamin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cuprenil | Cupripen</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Artamin | Byanodine | Cuprenil</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Artamin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cuprimine | Penicillamin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Artamin | Cuprimine | Cupripen</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Artamin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cuprimine | Distamin | Penicitin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Artamin | Cupripen | Trolovol</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cuprimine | Metalcaptase | Trolovol</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Artamin | Bianodin | Cuprenil</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cupripen</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Mifros</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Metalcaptase</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-7900739">
<a name="7900739"></a>Adelman HM, Winters PR, Mahan CS, et al, “D-Penicillamine-Induced Myasthenia Gravis; Diagnosis Obscured by Coexisting Chronic Obstructive Pulmonary Disease,” <i>Am J Med Sci</i>, 1995, 309(4):191-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/7900739/pubmed" id="7900739" target="_blank">7900739</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Advisory Committee on Childhood Lead Poisoning Prevention (ACCLPP). Low-level lead exposure harms children: A renewed call for primary intervention. January 4, 2012. Available at <a href="https://www.cdc.gov/nceh/lead/acclpp/final_document_030712.pdf%20" target="_blank">http://www.cdc.gov/nceh/lead/acclpp/final_document_030712.pdf</a>
</div>
</li>
<li>
<div class="reference">
                  Albert C, Aynard B, Terbe V, et al, “D-Penicillamine Induced Rapidly Progressive Glomerulonephritis With Membranous Nephropathy in a Patient With Rheumatoid Arthritis,” <i>Clin Exp Rheumatol</i>, 1994, 12(Suppl 11):108.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16199720">
<a name="16199720"></a>American Academy of Pediatrics (AAP) Committee on Environmental Health. Lead exposure in children: prevention, detection, and management. <i>Pediatrics.</i> 2005;116(4):1036-1046. doi:10.1542/peds.2005-1947<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/16199720/pubmed" id="16199720" target="_blank">16199720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7697959">
<a name="7697959"></a>Andonopoulos AP, Terzis E, and Tsibri E, “D-Penicillamine Induced Myasthenia Gravis in Rheumatoid Arthritis: An Unpredictable Common Occurrence?” <i>Clin Rheumatol</i>, 1994, 13(4):586-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/7697959/pubmed" id="7697959" target="_blank">7697959</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 104.</div>
</li>
<li>
<div class="reference">
                  Aronow R and Fleschmann LE, “Mercury Poisoning in Children,” <i>Clin Pediatr (Phila)</i>, 1976, 15(10):936-45.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21549078">
<a name="21549078"></a>Atzori L, Pinna AL, Pau M, Aste N. D-penicillamine elastosis perforans serpiginosa: description of two cases and review of the literature. <i>Dermatol Online J</i>. 2011;17(4):3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/21549078/pubmed" id="21549078" target="_blank">21549078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8804954">
<a name="8804954"></a>Boehler A, Vogt P, Speich R, Weder W, Russi EW. Bronchiolitis obliterans in a patient with localized scleroderma treated with D-penicillamine. <i>Eur Respir J</i>. 1996;9(6):1317-1319. doi:10.1183/09031936.96.09061317<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/8804954/pubmed" id="8804954" target="_blank">8804954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-122656">
<a name="122656"></a>Bucknall RC. Myasthenia associated with D-penicillamine therapy in rheumatoid arthritis. <i>Proc R Soc Med</i>. 1977;70 suppl 3(suppl 3):114-117.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/122656/pubmed" id="122656" target="_blank">122656</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Calello DP, Henretig FM. Lead. In: Nelson LS, Howland MA, Lewin NA, Smith SW, Hoffman RS, eds. <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. McGraw Hill Inc; 2018:1292-1308.</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC), <i>Guidelines for the Identification and Management of Lead Exposure in Pregnant and Lactating Women</i>, Atlanta: CDC; 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17975528">
<a name="17975528"></a>Centers for Disease Control and Prevention (CDC), “Interpreting and Managing Blood Lead Levels &lt;10 microg/dL in Children and Reducing Childhood Exposures to Lead: Recommendations of CDC's Advisory Committee on Childhood Lead Poisoning Prevention,” <i>MMWR Recomm Rep</i>, 2007, 56(RR-8):1-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/17975528/pubmed" id="17975528" target="_blank">17975528</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC), <i>Managing Elevated Blood Lead Levels Among Young Children: Recommendations from the Advisory Committee on Childhood Lead Poisoning Prevention</i>, Atlanta: CDC; 2002.</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC), Advisory Committee on Childhood Lead Poisoning Prevention. Low level lead exposure harms children: a renewed call for primary prevention. January 4, 2012. Available at <a href="https://www.cdc.gov/nceh/lead/acclpp/final_document_030712.pdf" target="_blank">https://www.cdc.gov/nceh/lead/acclpp/final_document_030712.pdf</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20889734">
<a name="20889734"></a>Chandran L and Cataldo R, “Lead Poisoning: Basics and New Developments,” <i>Pediatr Rev</i>, 2010, 31(10):399-406.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/20889734/pubmed" id="20889734" target="_blank">20889734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20791222">
<a name="20791222"></a>Crawhall JC, Scowen EF, Thompson CJ, Watts RW. Dissolution of cystine stones during d-penicillamine treatment of a pregnant patient with cystinuria.<i> Br Med J.</i> 1967;2(5546):216-218.1. doi: 10.1136/bmj.2.5546.216.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/20791222/pubmed" id="20791222" target="_blank">20791222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7605532">
<a name="7605532"></a>Cullen NM, Wolf LR, and St Clair D, “Pediatric Arsenic Ingestion,” <i>Am J Emerg Med</i>, 1995, 13(4):432-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/7605532/pubmed" id="7605532" target="_blank">7605532</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Cuprimine (penicillamine) [product monograph]. Laval, Quebec, Canada: Bausch Health, Canada Inc; December 2019.</div>
</li>
<li>
<div class="reference">
                  Cuprimine (penicillamine) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; November 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27350316">
<a name="27350316"></a>Dathe K, Beck E, Schaefer C. Pregnancy outcome after chelation therapy in Wilson disease. Evaluation of the German Embryotox Database. <i>Reprod Toxicol.</i> 2016;65:39-45. doi: 10.1016/j.reprotox.2016.06.015.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/27350316/pubmed" id="27350316" target="_blank">27350316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7268676">
<a name="7268676"></a>Davies D, Jones JK. Pulmonary eosinophilia caused by penicillamine. <i>Thorax</i>. 1980;35(12):957-958. doi:10.1136/thx.35.12.957<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/7268676/pubmed" id="7268676" target="_blank">7268676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18951580">
<a name="18951580"></a>DeBerardinis RJ, Coughlin CR 2nd, Kaplan P. Penicillamine therapy for pediatric cystinuria: experience from a cohort of American children. <i>J Urol</i>. 2008;180(6):2620-2623.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/18951580/pubmed" id="18951580" target="_blank">18951580</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Depen (penicillamine) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals Inc; January 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22340672">
<a name="22340672"></a>European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson's disease. <i>J Hepatol</i>. 2012;56(3):671-685.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/22340672/pubmed" id="22340672" target="_blank">22340672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34101387">
<a name="34101387"></a>Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. <i>Arthritis Care Res (Hoboken).</i> 2021;73(7):924-939. doi:10.1002/acr.24596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/34101387/pubmed" id="34101387" target="_blank">34101387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17189579">
<a name="17189579"></a>Gracia RC and Snodgrass WR, “Lead Toxicity and Chelation Therapy," <i>Am J Health Syst Pharm</i>, 2007, 64(1):45-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/17189579/pubmed" id="17189579" target="_blank">17189579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7143525">
<a name="7143525"></a>Hryhorczuk DO, Meyers L, and Chen G, “Treatment of Mercury Intoxication in a Dentist With N-Acetyl-D,L-Penicillamine,” <i>J Toxicol Clin Toxicol</i>, 1982, 19(4):401-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/7143525/pubmed" id="7143525" target="_blank">7143525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18677552">
<a name="18677552"></a>Kaga F, Kodama H, Siga K et al. Copper and zinc status in the breast milk of mothers with Wilson disease [abstract taken from: Abstracts of the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism. <i>J Inherit Metab Dis.</i> 2008;31(suppl 1):1-192].<i> J Inherit Metab Dis.</i> 2008;31(suppl 1):157. doi: 10.1007/s10545-008-9975-0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/18677552/pubmed" id="18677552" target="_blank">18677552</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kandola L, Swannell AJ, and Hunter A, “Acquired Sideroblastic Anaemia Associated With Penicillamine Therapy for Rheumatoid Arthritis,” <i>Ann Rheum Dis</i>, 1995, 54(6):529-30.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2692700">
<a name="2692700"></a>Katz LJ, Lesser RL, Merikangas JR, Silverman JP. Ocular myasthenia gravis after D-penicillamine administration. <i>Br J Ophthalmol</i>. 1989;73(12):1015-1018. doi:10.1136/bjo.73.12.1015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/2692700/pubmed" id="2692700" target="_blank">2692700</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15602663">
<a name="15602663"></a>Knoll T, Zöllner A, Wendt-Nordahl G, Michel MS, Alken P. Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up. <i>Pediatr Nephrol</i>. 2005;20(1):19-24. doi:10.1007/s00467-004-1663-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/15602663/pubmed" id="15602663" target="_blank">15602663</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lifshitz M and Levy J, “Efficacy of D-Penicillamine in Reducing Lead Concentrations in Children: A Prospective, Uncontrolled Study,” <i>J Pharm Technol</i>, 2000, 16(3):98-101.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6939892">
<a name="6939892"></a>Lyle WH, “Penicillamine in Metal Poisoning,” <i>J Rheumatol Suppl</i>, 1981, 7:96-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/6939892/pubmed" id="6939892" target="_blank">6939892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1009359">
<a name="1009359"></a>Marsden RA, Vanhegan RI, Walshe M, Hill H, Mowat AG. Pemphigus foliaceus induced by penicillamine. <i>Br Med J</i>. 1976;2(6049):1423-1424. doi:10.1136/bmj.2.6049.1423<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/1009359/pubmed" id="1009359" target="_blank">1009359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1551638">
<a name="1551638"></a>Martins da Costa C, Baldwin D, Portmann B, Lolin Y, Mowat AP, Mieli-Vergani G. Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease. <i>Hepatology</i>. 1992;15(4):609-615.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/1551638/pubmed" id="1551638" target="_blank">1551638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17449133">
<a name="17449133"></a>Müller T, Koppikar S, Taylor RM, et al. Re-evaluation of the penicillamine challenge test in the diagnosis of Wilson's disease in children. <i>J Hepatol</i>. 2007;47(2):270-276.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/17449133/pubmed" id="17449133" target="_blank">17449133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7253120">
<a name="7253120"></a>Multz CV, “Cholestatic Hepatitis Caused by Penicillamine,” <i>JAMA</i>, 1981, 246(6):674-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/7253120/pubmed" id="7253120" target="_blank">7253120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11920335">
<a name="11920335"></a>Nagahama K, Matsushita H, Hara M, Ubara Y, Hara S, Yamada A. Bucillamine induces membranous glomerulonephritis. <i>Am J Kidney Dis</i>. 2002;39(4):706-712.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/11920335/pubmed" id="11920335" target="_blank">11920335</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7726755">
<a name="7726755"></a>Negishi M, Matsuda A, Kaga S, et al, “A Case of Agranulocytosis Which Occurred Several Hours After the Readministration of D-Penicillamine Accompanied by Shivering-Chillness,” <i>Arerugi</i>, 1995, 44(2):96-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/7726755/pubmed" id="7726755" target="_blank">7726755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8333453">
<a name="8333453"></a>Oga M, Matsui N, Anai T, et al, “Copper Disposition of the Fetus and Placenta in a Patient With Untreated Wilson's Disease,” <i>Am J Obstet Gynecol</i>, 1993, 169(1):196-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/8333453/pubmed" id="8333453" target="_blank">8333453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12580366">
<a name="12580366"></a>Piomelli S, “Childhood Lead Poisoning,” <i>Pediatr Clin North Am</i>, 2002, 49(6):1285-304.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/12580366/pubmed" id="12580366" target="_blank">12580366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-466063">
<a name="466063"></a>Reeback J, Benton S, Swash M, Schwartz MS. Penicillamine-induced neuromyotonia. <i>Br Med J</i>. 1979;1(6176):1464-1465. doi:10.1136/bmj.1.6176.1464<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/466063/pubmed" id="466063" target="_blank">466063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18506894">
<a name="18506894"></a>Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. American Association for Study of Liver Diseases (AASLD). <i>Hepatology.</i> 2008;47(6):2089-2111. doi:10.1002/hep.22261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/18506894/pubmed" id="18506894" target="_blank">18506894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3738805">
<a name="3738805"></a>Rosa FW, “Teratogen Update. Penicillamine,” <i>Teratology</i>, 1986, 33(1):127-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/3738805/pubmed" id="3738805" target="_blank">3738805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7387219">
<a name="7387219"></a>Rosenbaum J, Katz WA, Schumacher HR. Hepatotoxicity associated with use of D-penicillamine in rheumatoid arthritis. <i>Ann Rheum Dis</i>. 1980;39(2):152-154. doi:10.1136/ard.39.2.152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/7387219/pubmed" id="7387219" target="_blank">7387219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2563402">
<a name="2563402"></a>Rosenberg AM. “Advanced Drug Therapy for Juvenile Rheumatoid Arthritis,” <i>J Pediatr</i>, 1989, 114(2):171-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/2563402/pubmed" id="2563402" target="_blank">2563402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-851751">
<a name="851751"></a>Scherak O, Kolarz G, Molubar K. Pemphigus erythematosus-like rash in a patient on penicillamine. <i>Br Med J</i>. 1977;1(6064):838. doi:10.1136/bmj.1.6064.838-c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/851751/pubmed" id="851751" target="_blank">851751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36152019">
<a name="36152019"></a>Schilsky ML, Roberts EA, Bronstein JM, et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: executive summary of the 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases. <i>Hepatology</i>. Published online December 7, 2022. doi:10.1002/hep.32805<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/36152019/pubmed" id="36152019" target="_blank">36152019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32918941">
<a name="32918941"></a>Servais A, Thomas K, Dello Strologo L, et al. Cystinuria: clinical practice recommendation. <i>Kidney Int</i>. 2021;99(1):48-58. doi:10.1016/j.kint.2020.06.035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/32918941/pubmed" id="32918941" target="_blank">32918941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3361395">
<a name="3361395"></a>Shannon M, Graef J, Lovejoy FH Jr. Efficacy and toxicity of D-penicillamine in low-level lead poisoning. <i>J Pediatr</i>. 1988;112(5):799-804. doi:10.1016/s0022-3476(88)83212-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/3361395/pubmed" id="3361395" target="_blank">3361395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10669180">
<a name="10669180"></a>Shannon MW, Townsend MK. Adverse effects of reduced-dose d-penicillamine in children with mild-to-moderate lead poisoning. <i>Ann Pharmacother</i>. 2000;34(1):15-18. doi:10.1345/aph.19084<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/10669180/pubmed" id="10669180" target="_blank">10669180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5421930">
<a name="5421930"></a>Smith DB and Gallagher BB, “The Effect of Penicillamine on Seizure Threshold. The Role of Pyridoxine,” <i>Arch Neurol</i>, 1970, 23(1):59-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/5421930/pubmed" id="5421930" target="_blank">5421930</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29341979">
<a name="29341979"></a>Socha P, Janczyk W, Dhawan A, et al. Wilson's disease in children: a position paper by the Hepatology Committee of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. <i>J Pediatr Gastroenterol Nutr</i>. 2018;66(2):334-344. doi:10.1097/MPG.0000000000001787<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/29341979/pubmed" id="29341979" target="_blank">29341979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7350870">
<a name="7350870"></a>Stein HB, Patterson AC, Offer RC, et al, “Adverse Effects of D-Penicillamine in Rheumatoid Arthritis,” <i>Ann Intern Med</i>, 1980, 92:24-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/7350870/pubmed" id="7350870" target="_blank">7350870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-420710">
<a name="420710"></a>Sundstrom WR, Schuna AA. Penicillamine-induced myasthenia gravis. <i>Arthritis Rheum</i>. 1979;22(2):197-198. doi:10.1002/art.1780220214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/420710/pubmed" id="420710" target="_blank">420710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17043508">
<a name="17043508"></a>Swarup A, Sachdeva N, and Schumacher Jr HP, “Dosing of Antirheumatic Drugs in Renal Disease and Dialysis,” <i>J Clin Rheumatol</i>, 2004, 10(4):190-204.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/17043508/pubmed" id="17043508" target="_blank">17043508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15339083">
<a name="15339083"></a>Szegedi A, Surányi P, Szücs G, Kiss M, Hunyadi J, Gaál J. D-penicillamine-induced pemphigus vulgaris in a patient with scleroderma-rheumatoid arthritis overlap syndrome. <i>Acta Derm Venereol.</i> 2004;84(4):318-319. doi:10.1080/00015550410026399<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/15339083/pubmed" id="15339083" target="_blank">15339083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3707633">
<a name="3707633"></a>Takahashi K, Ogita T, Okudaira H, Yoshinoya S, Yoshizawa H, Miyamoto T. D-penicillamine-induced polymyositis in patients with rheumatoid arthritis. <i>Arthritis Rheum</i>. 1986;29(4):560-564. doi:10.1002/art.1780290416<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/3707633/pubmed" id="3707633" target="_blank">3707633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7596706">
<a name="7596706"></a>“Treatment Guidelines for Lead Exposure in Children. American Academy of Pediatrics Committee on Drugs,” <i>Pediatrics</i>, 1995, 96(1 Pt 1):155-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/7596706/pubmed" id="7596706" target="_blank">7596706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7452649">
<a name="7452649"></a>Wojnarowska F. Dermatomyositis induced by penicillamine. <i>J R Soc Med</i>. 1980;73(12):884-886. doi:10.1177/014107688007301213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillamine-d-penicillamine-pediatric-drug-information/abstract-text/7452649/pubmed" id="7452649" target="_blank">7452649</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12685 Version 206.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
